Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 801–900 of 2,932
Zhan, L., Tian, X., Lin, J., Zhang, Y., Zheng, H., Peng, X., & Zhao, G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109849 · Cited by 19
Spruijtenburg, B., Rudramurthy, S. M., Meijer, E. F. J., van Haren, M. H. I., Kaur, H., Chakrabarti, A., Meis, J. F. G. M., & de Groot, T. (2023) · Microorganisms · doi:10.3390/microorganisms11061525 · Cited by 20
“5 million deaths every year, which appears to be increasing [1,2].”
BackgroundPfaller, M. A., Carvalhaes, C. G., & Castanheira, M. (2023) · Mycoses · doi:10.1111/myc.13620 · Cited by 22
Laboratory and clinical management capacity for invasive fungal infections: the Italian landscape
Vena, A., Bassetti, M., Mezzogori, L., Marchesi, F., Hoenigl, M., Giacobbe, D. R., Corcione, S., Bartoletti, M., Stemler, J., Pagano, L., et al. (2023) · Infection · doi:10.1007/s15010-023-02084-x · Cited by 18
Sasoni, N., Caracciolo, B., Cabeza, M. S., Gamarra, S. P., Carnovale, S., & García‐Effrón, G. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00968-23 · Cited by 22
Hurraß, J., Heinzow, B., Walser‐Reichenbach, S., Aurbach, U., Becker, S., Bellmann, R., Bergmann, K., Cornely, O. A., Engelhart, S., Fischer, G., et al. (2024) · Allergologie select · doi:10.5414/alx02444e · Cited by 24
Inferring fungal growth rates from optical density data
Hameed, T., Motsi, N., Bignell, E., & Tanaka, R. J. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012105 · Cited by 20
“Combatting fungal infections is essential for treating patients with life-threatening invasive infections [1].”
BackgroundBrilacidin, a novel antifungal agent against Cryptococcus neoformans
Diehl, C., Pinzan, C. F., de Castro, P. A., Delbaje, E., García-Carnero, L. C., Sánchez‐León, E., Bhalla, K., Kronstad, J. W., Kim, D.-G., Doering, T. L., et al. (2024) · mBio · doi:10.1128/mbio.01031-24 · Cited by 19
Ball, B., Sukumaran, A., Krieger, J. R., & Geddes‐McAlister, J. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00255 · Cited by 21
Anti-fungal T cell responses in the lung and modulation by the gut-lung axis
Scheffold, A., & Bächer, P. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.06.006 · Cited by 19
Signaling C-Type Lectin Receptors in Antifungal Immunity
Höft, M. A., Hoving, J. C., & Brown, G. D. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_224 · Cited by 20
Perea, J. R. A., Grau, S., Vázquez, L., Rebollo, P., Peral, C., de Aldecoa, A. L., & López-Gómez, V. (2020) · Mycoses · doi:10.1111/myc.13189 · Cited by 18
Vasileiou, E., Paisiou, A., Tsipou, C., Pourtsidis, A. G., Galani, V., Katzilakis, N., Antoniadi, K., Papakonstantinou, Ε., Ioannidou, E., Stiakaki, E., et al. (2020) · Journal of Fungi · doi:10.3390/jof6040276 · Cited by 20
Proteomics of Cryptococcus neoformans: From the Lab to the Clinic
Muselius, B., Durand, S.-L., & Geddes‐McAlister, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212390 · Cited by 21
“In humans, fungal pathogens represent substantial threats to global health, with more than 300 million people afflicted by serious fungal diseases annually [1].”
Wu, H., Du, C., Xu, Y., Liu, L., Zhou, X., & Ji, Q. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114208 · Cited by 19
Santos, A. L., Beckham, J. L., Liu, D., Li, G., van Venrooy, A. R., Oliver, A., Tegos, G. P., & Tour, J. M. (2023) · Advanced Science · doi:10.1002/advs.202205781 · Cited by 19
Trapani, F., Viceconte, G., Morena, V., Tiseo, G., Mori, G., Kölking, B., & Khatamzas, E. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf034 · Cited by 18
Sehgal, I. S., Kathirvel, S., Agarwal, R., Muthu, V., Dhooria, S., Prasad, K. T., Salzer, H. J. F., Cornely, O. A., Aggarwal, A. N., & Chakrabarti, A. (2025) · Mycoses · doi:10.1111/myc.70060 · Cited by 19
“CPA is the second most common Aspergillus - related lung disease in humans, affecting over 3 million people globally, and ranking third among fungus-related deaths in humans [4, 5].”
Aspergillus fumigatus dsRNA virus promotes fungal fitness and pathogenicity in the mammalian host
Rocha, M. C., Lerer, V., Adeoye, J. A., Hayby, H., Fabre, M. L., Barber, A. E., & Shlezinger, N. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02096-3 · Cited by 22
“Furthermore, epidemiologists anticipate a consistent rise in IFI cases due to the growing population of individuals with compromised immune systems 2 .”
Susan, V., Lang, M., Sabou, M., & Bourel‐Bonnet, L. (2025) · Pharmaceuticals · doi:10.3390/ph18081220 · Cited by 30
“5 Invasive aspergillosis affects 2,113,000 humans worlwide per year, in the context of chronic obstructive pulmonary disease [13], intensive care [24], hematopoetic stem cell transplant [25], leukemia, and lymphoma [26].”
Butyrolactol A enhances caspofungin efficacy via flippase inhibition in drug-resistant fungi
Chen, X., Duan, H. D., Hoy, M. J., Koteva, K. K., Spitzer, M., Guitor, A. K., Puumala, E., Fiebig‐Comyn, A., Hu, G., Yiu, B., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.036 · Cited by 27
PlantAFP: a curated database of plant-origin antifungal peptides
Tyagi, A. K., Pankaj, V., Singh, S. K., Roy, S., Semwal, M., Shasany, A. K., & Sharma, A. K. (2019) · Amino Acids · doi:10.1007/s00726-019-02792-5 · Cited by 17
“Therefore, in developing countries like Asia and Africa, the rate of mortality is reaching near to 50 to 100% due to fungal infection (Bongomin et al. 2017).”
BackgroundEstimated Burden of Fungal Infections in Oman
Al‐Hatmi, A. M. S., Shuhoumi, M. A. A., & Denning, D. W. (2020) · Journal of Fungi · doi:10.3390/jof7010005 · Cited by 19
“[32], they estimated an average incidence rate of 29 countries reporting intra-abdominal candidiasis (Candida peritonitis) and revealed a 1.”
BackgroundMethodInfluentialSelf-citationRollin‐Pinheiro, R., Borba-Santos, L. P., Xisto, M. I. D. D. S., de Castro-Almeida, Y., Rochetti, V. P., Rozental, S., & Barreto‐Bergter, E. (2021) · Journal of Fungi · doi:10.3390/jof7100803 · Cited by 19
“Fungal infections have been emerging during the last decades as a consequence of increasing numbers of individuals suffering from health problems, such as diabetes, chemotherapy for cancer treatment, HIV/AIDS, and other immunosuppressive conditions [1,2].”
BackgroundExhaled Volatile Organic Compounds for Identifying Patients With Chronic Pulmonary Aspergillosis
Li, Z., Zeng, P., Chen, Z., Guan, W., Wang, T., Lin, Y., Li, S., Zhang, Z., Zhan, Y., Wang, M.-D., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.720119 · Cited by 19
“Pulmonary aspergillosis is common in immunosuppressed patients and a major global health burden, affecting more than 3 million people worldwide (1, 2).”
BackgroundRule, R., Mitton, B. C., Govender, N. P., Hoffmann, D. E., & Said, M. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30979-8 · Cited by 19
Hsp90 interaction networks in fungi—tools and techniques
Crunden, J. L., & Diezmann, S. (2021) · FEMS Yeast Research · doi:10.1093/femsyr/foab054 · Cited by 18
“This yeast causes ∼750 000 life-threatening invasive infections world-wide each year with mortality rates of up to 75% (Brown et al. 2012; Bongomin et al. 2017).”
BackgroundInfluentialEvaluation of the Vitek Ms system for the identification of filamentous fungi
Zvezdánova, M. E., Escribano, P., Guinea, J., Muñóz, P., Rodríguez‐Temporal, D., & Rodríguez‐Sánchez, B. (2022) · Medical Mycology · doi:10.1093/mmy/myac027 · Cited by 17
Rozaliyani, A., Abdullah, A., Setianingrum, F., Sjamsuridzal, W., Wahyuningsih, R., Bowolaksono, A., Fatril, A. E., Adawıyah, R., Tugiran, M., Sjam, R., et al. (2022) · Journal of Fungi · doi:10.3390/jof8040411 · Cited by 19
“About three million CPA cases occur worldwide [1].”
BackgroundSelf-citationGaspar‐Cordeiro, A., Amaral, C., Pobre, V., Antunes, W., Petronilho, A., Paixão, P., Matos, A., & Pimentel, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.920574 · Cited by 18
Epidemiology of Aspergillosis in Cancer Patients in Taiwan
Chen, C., Ho, C., Wu, Y.-C., Chen, Y., Wang, J., & Liao, K. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s370967 · Cited by 18
“5 million, and more than 150 million people had serious fungal diseases, which have a major impact in the world.(7) There is an increasing incidence of invasive pulmonary aspergillosis in Taiwan for males from 0.”
BackgroundGil, F., Laiolo, J., Bayona-Pacheco, B. L., Cannon, R. D., Ferreira‐Pereira, A., & Carpinella, M. C. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03745-4 · Cited by 19
An old confusion: Entomophthoromycosis versus mucormycosis and their main differences
Acosta-España, J. D., & Voigt, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1035100 · Cited by 22
“The attention is focused on the most common diseases such as cryptococcal meningitis, invasive candidiasis, Pneumocystis jirovecii pneumonia, invasive aspergillosis, fungal asthma, and fungal keratitis (Bongomin et al., 2017).”
BackgroundWu, Y., Chen, Y., Lu, H., & Ying, C. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106819 · Cited by 19
Spoladori, L. F. D. A., Andriani, G. M., de Castro, I. M., Suzukawa, H. T., Gimenes, A. C. R., Bartolomeu-Gonçalves, G., Ishida, K., Nakazato, G., Pinge‐Filho, P., Machado, R. R. B., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12050861 · Cited by 19
“5 million people are estimated to die due to fungal infections [2].”
BackgroundFungal mechanisms of intracellular survival: what can we learn from bacterial pathogens?
Stuckey, P. V., & Santiago-Tirado, F. H. (2023) · Infection and Immunity · doi:10.1128/iai.00434-22 · Cited by 22
Rodrigues, D. S., Cabral, V. P. D. F., Barbosa, A. D., Sá, L. G. D. A. V., da Silva, C. R., Moreira, L. E. A., Neto, J. B., Silva, J., dos Santos, H. S., Marinho, E. S., et al. (2023) · Future Microbiology · doi:10.2217/fmb-2022-0254 · Cited by 22
Hassan, S. U., Khalid, S. H., Hussain, L., Imam, M. T., & Shahid, I. (2023) · Gels · doi:10.3390/gels9110841 · Cited by 25
“According to the most prominent international fungal education (LIFE) portal, over 80% of people are susceptible to developing fungal infections [1,2].”
BackgroundAntifungal activity of tannic acid against Candida spp. and its mechanism of action
Moreira, L. E. A., Cabral, V. P. D. F., Rodrigues, D. S., Barbosa, A. D., Silveira, M. J. C. B., Coutinho, T. D. N. P., Barbosa, S. A., Sá, L. G. D. A. V., Neto, J. B. D. A., da Rocha, S. N. C., et al. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-024-01477-w · Cited by 21
Combatting Fungal Infections: Advances in Antifungal Polymeric Nanomaterials
Schaefer, S., Corrigan, N. A., Brunke, S., Lenardon, M. D., & Boyer, C. A. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00866 · Cited by 19
Seyedmousavi, S., Davis, M. J., Sugui, J. A., Pinkhasov, T., Moyer, S., Salazar, A. M., Chang, Y. C., & Kwon-Chung, K. J. (2018) · mBio · doi:10.1128/mbio.00422-18 · Cited by 17
Fungal infections in pediatric neurosurgery
Cáceres, A., Avila, M. L., & Herrera, M. L. (2018) · Child s Nervous System · doi:10.1007/s00381-018-3942-3 · Cited by 17
Otu, A. A., Langridge, P., & Denning, D. W. (2019) · Mycoses · doi:10.1111/myc.12996 · Cited by 20
“Among those who stopped using the nebulised therapy before their next clinic visit, reasons cited included increased breath‐ lessness (8), wheeze (7), bronchospasm (6), sore throat/voice (4), coughing (4), chest tightness (3), light‐headedness/dizziness (2), diarrhoea (2), fatigue (2), mouth blisters/ulcers (2), heada…”
BackgroundSelf-citationAntimicrobial activities of Tephrosia vogelii against selected pathogenic fungi and bacteria strains
Mlozi, S. H., Mmongoyo, J. A., & Chacha, M. N. (2019) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2019.1705929 · Cited by 20
“Nevertheless, little attention is paid to fungal diseases hence resulting in fewer efforts in searching for potential alternative antifungal agents against these opportunistic fungi which cause life-threatening fungal diseases (Bongomin et al. 2017; Rodrigues and Albuquerque 2018).”
BackgroundInfluentialWani, M. Y., Ahmad, A., Aqlan, F. M., & Al‐Bogami, A. S. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00030 · Cited by 18
Siopi, M., Rivero-Menéndez, O., Gkotsis, G., Panara, A., Τhomaidis, Ν. S., Alastruey‐Izquierdo, A., Pournaras, S., & Meletiadis, J. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa316 · Cited by 21
Sec14 family of lipid transfer proteins in yeasts
Holič, R., Šťastný, D., & Griač, P. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158990 · Cited by 24
Arunga, S., Mbarak, T., Ebong, A., et al. (2021) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2020-000698 · Cited by 17
A Histoplasma capsulatum Lipid Metabolic Map Identifies Antifungal Targets
Zamith‐Miranda, D., Heyman, H. M., Burnet, M., Couvillion, S., Zheng, X., Munoz, N., Nelson, W. C., Kyle, J. E., Zink, E. M., Weitz, K., et al. (2021) · mBio · doi:10.1128/mbio.02972-21 · Cited by 21
“0 Fold Enrichment C D Cer(6) IPC(5) HexCer(1) CL(10) PA(7)”
BackgroundNovel Treatment Approach for Aspergilloses by Targeting Germination
Verburg, K., van Neer, J., Duca, M., & de Cock, H. (2022) · Journal of Fungi · doi:10.3390/jof8080758 · Cited by 21
“It was found that chronic pulmonary aspergillosis (CPA), a chronic Aspergillus infection, is more common in patients with damaged lung tissue and/or pulmonary diseases [30,31].”
BackgroundSystemic fungal infections: A pharmacist/researcher perspective
Spencer, A. C., Brubaker, K. R., & Garneau‐Tsodikova, S. (2022) · Fungal Biology Reviews · doi:10.1016/j.fbr.2022.11.001 · Cited by 19
Edwards, H. M., Cogliati, M., Kwenda, G., & Fisher, M. C. (2021) · FEMS Microbiology Ecology · doi:10.1093/femsec/fiab093 · Cited by 20
“Fungal diseases cause a considerable and underappreciated burden of disease worldwide (Bongomin et al. 2017).”
BackgroundBhatia, S., Al‐Harrasi, A., Almohana, I. H., Albayati, M. S., Jawad, M., Shah, Y. A., Ullah, S., Philip, A. K., Halim, S. A., Khan, A., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24210 · Cited by 17
“A recent report showed that fungal infections caused almost 1.7 million deaths annually [1].”
BackgroundInfluentialExploring the bioactive landscape: peptides and non-peptides from the human microbiota
Shah, A. B., Cho, H., & Shim, S. H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00713-x · Cited by 21
“Bacterial fermentation of prebioticsresultsintheproductionofSCFAs,includingacetate,propionate, and butyrate, which are key metabolites in fl uencing host health 111,112 .”
Toledo, E. B., Lucas, D. R., Simão, T. L. B. V., Calixto, S. D., Lasunskaia, E., Muzitano, M. F., Damica, F. Z., Gomes, V. M., & Carvalho, A. D. O. (2021) · Amino Acids · doi:10.1007/s00726-020-02929-x · Cited by 18
Inositol polyphosphate–protein interactions: Implications for microbial pathogenicity
Lev, S., Bowring, B. G., Desmarini, D., & Djordjevic, J. T. (2021) · Cellular Microbiology · doi:10.1111/cmi.13325 · Cited by 16
Drug–drug interaction database for safe prescribing of systemic antifungal agents
Niazi-Ali, S., Atherton, G. T., Walczak, M., & Denning, D. W. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211010605 · Cited by 21
Self-citationCatalytic defense against fungal pathogens using nanozymes
Wu, Q., Zou, S., Wang, Q., Chen, L., Yan, X., & Gao, L. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0084 · Cited by 16
Liu, Y., Zhang, Y., Zhao, X., Lu, W., Zhong, Y., & Fu, Y. V. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04562-22 · Cited by 20
Burden of fungal infections in Kenya
Ratemo, S. N., & Denning, D. W. (2023) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2023.2204112 · Cited by 20
“To estimate the annual incidence of candidemia, we assumed a rate of 5/100,000, this being the mean of 2–11/100,000 persons (Arendrup 2010; Bongomin et al. 2017).”
BackgroundSelf-citationKrylov, V. B., Gómez‐Redondo, M., Solovev, A. S., Yashunsky, D. V., Brown, A. J. P., Stappers, M. H. T., Gow, N. A. R., Ardá, A., Jiménez‐Barbero, J., & Nifantiev, N. E. (2023) · The Cell Surface · doi:10.1016/j.tcsw.2023.100109 · Cited by 18
How metals fuel fungal virulence, yet promote anti-fungal immunity
Alselami, A., & Drummond, R. A. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050393 · Cited by 18
The Gordian Knot of C. auris: If You Cannot Cut It, Prevent It
Rapti, V., Iliopoulou, K., & Poulakou, G. (2023) · Pathogens · doi:10.3390/pathogens12121444 · Cited by 20
Different forms of pulmonary aspergillosis: A pictorial essay
Tamkevičiūtė, L., Tumėnas, A., Zaveckienė, J., Irion, K., Franquet, T., & Radike, M. (2024) · European Journal of Radiology · doi:10.1016/j.ejrad.2024.111290 · Cited by 19
Plastiphily is linked to generic virulence traits of important human pathogenic fungi
Gkoutselis, G., Rohrbach, S., Harjes, J., Brachmann, A., Horn, M. A., & Rambold, G. (2024) · Communications Earth & Environment · doi:10.1038/s43247-023-01127-3 · Cited by 21
Re-estimation of the burden of serious fungal diseases in Uganda
Bongomin, F., Kwizera, R., Namusobya, M. S., van Rhijn, N., Biraro, I. A., Kirenga, B., Meya, D. B., & Denning, D. W. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241228345 · Cited by 21
“54 However, most superficial fungal infections such as pityriasis versicolor and tinea corporis are mainly asymptomatic and not life-threatening.”
BackgroundInfluentialSelf-citationTranscriptomic meta-analysis to identify potential antifungal targets in Candida albicans
Hefny, Z. A., Ji, B., Elsemman, I. E., Nielsen, J., & Dijck, P. V. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03213-8 · Cited by 18
“Every year, 150 million people are infected with fungal pathogens which results in almost 1.7 million deaths yearly [1, 2].”
BackgroundInfluentialEvolutionary trends in antifungal resistance: a meta-analysis
Niu, X., Al‐Hatmi, A. M. S., Vitale, R. G., Lackner, M., Ahmed, S. A., Verweij, P. E., Kang, Y., & de Hoog, S. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02127-23 · Cited by 16
Vélez, N., Argel, A., Kissmann, A., Alpízar-Pedraza, D., Escandón, P., Rosenau, F., Ständker, L., & Firacative, C. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1389020 · Cited by 19
Washington, E., Zhou, Y., Hsu, A. L., Petrovich, M., Tenor, J. L., Toffaletti, D. L., Guan, Z., Perfect, J. R., Borgnia, M. J., Bartesaghi, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314087121 · Cited by 21
“Invasive fungal diseases (IFDs) caused by pathogenic fungi such as Cryptococcus , Candida, and Aspergillus are a major threat to human health, resulting in more than one and a half million deaths worldwide each year (1, 2).”
BackgroundShaping the future of medicine through diverse therapeutic applications of tetralin derivatives
Shah, B. M., & Kachhadiya, R. N. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03331-y · Cited by 22
“Fungal infections are extremely common and impact more than one billion individuals globally each year [24].”
Prosty, C. J., Luo, O. D., Khalaf, R., Corpo, O. D., McDonald, E. G., & Lee, T. C. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.11.004 · Cited by 20
Rezaie, S., Zareshahrabadi, Z., Zomorodian, K., et al. (2020) · Journal of Microbiology Biotechnology and Food Sciences · doi:10.15414/jmbfs.2020.10.1.5-11 · Cited by 16
Fluorescent peptides for imaging of fungal cells
Zhao, C., Mendive‐Tapia, L., & Vendrell, M. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.11.018 · Cited by 16
Glycobiology of Human Fungal Pathogens: New Avenues for Drug Development
Lee, D. J., O’Donnell, H., Routier, F. H., Tiralongo, J., & Haselhorst, T. (2019) · Cells · doi:10.3390/cells8111348 · Cited by 15
“Invasive candidiasis is predicted to increase to more than 700,000 cases annually worldwide [9,16,20].”
BackgroundInfluentialIncorporation of 2-amino-thiophene derivative in nanoparticles: enhancement of antifungal activity
Neves, W. W., Neves, R. P., Macêdo, D. P. C., Eleamen, G. R. D. A., Kretzschmar, E. A. D. M., Oliveira, E. E., Mendonça, F. J. B., & de Lima-Neto, R. G. (2020) · Brazilian Journal of Microbiology · doi:10.1007/s42770-020-00248-7 · Cited by 20
Advances in Molecular Tools and In Vivo Models for the Study of Human Fungal Pathogenesis
Malavia, D., Gow, N. A. R., & Usher, J. (2020) · Microorganisms · doi:10.3390/microorganisms8060803 · Cited by 16
“At least one-quarter of the human population will experience a superficial mucosal fungal infection during their lifetime, however, life-threatening infections occur less frequently but now at an increasing rate due to medical advancements and ability of populations to have longer lifespans and patients to survive tra…”
BackgroundBiofilm Formation by Histoplasma capsulatum in Different Culture Media and Oxygen Atmospheres
Gonçalves, L. N. C., Costa-Orlandi, C. B., Bila, N. M., Vaso, C. O., da Silva, R. A. M., Mendes‐Giannini, M. J. S., Taylor, M. L., & Fusco‐Almeida, A. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01455 · Cited by 20
Lactoferrin-Derived Peptide Lactofungin Is Potently Synergistic with Amphotericin B
Fernandes, K. E., Payne, R. J., & Carter, D. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00842-20 · Cited by 18
“Candida and Cryptococcus species are among the main causative agents of opportunistic mycoses and are associated with high mortality and morbidity rates (2).”
BackgroundAccelerated vs. conventional collagen cross‑linking for infectious keratitis
Barac, I. R., Baltă, G., Zemba, M., et al. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9716 · Cited by 16
da Silva, L. J., Barroso, F. D. D., Vieira, L. S., Mota, D. R. C., Firmino, B. K. D. S., da Silva, C. R., Cabral, V. P. D. F., Cândido, T. M., Sá, L. G. D. A. V., da Silva, W. M. B., et al. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001308 · Cited by 18
Wong, S. S. W., Venugopalan, L. P., Beaussart, A., Karnam, A., Mohammed, M. R. S., Jayapal, J. M., Bretagne, S., Bayry, J., Lalitha, P., Dharmalingam, K., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.643312 · Cited by 17
Yousefian, S., Dastan, F., Marjani, M., Tabarsi, P., Barati, S., Shahsavari, N., & Kobarfard, F. (2021) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2021/5497427 · Cited by 18
“Global incidence of invasive aspergillosis is 300,000 cases annually (50% of them are in Asian countries), and the mortality rate is 30–80% [4].”
BackgroundZuzarte, M., Correia, P. M. P., Alves-Silva, J. M., Gonçalves, M. J., Cavaleiro, C., Cruz, M. T., & Salgueiro, L. (2021) · Antibiotics · doi:10.3390/antibiotics10050592 · Cited by 17
“6 million deaths worldwide, thus presenting a huge socio-economic burden, frequently neglected by public health authorities [1].”
BackgroundBen-Ghazzi, N., Moreno-Velásquez, S. D., Seidel, C., Thomson, D. D., Denning, D. W., Read, N. D., Bowyer, P., & Gago, S. (2021) · Journal of Fungi · doi:10.3390/jof7060454 · Cited by 19
“More than 10 million people globally suffer from lung diseases caused by the environmental fungus Aspergillus fumigatus [1], and over 200,000 annually die from it [2].”
BackgroundSelf-citationLee, M., Huang, H., Keng, L., Chang, H., Sheu, C., Fu, P., Wang, J., Chong, I., Shih, J., & Yu, C. (2021) · Journal of Fungi · doi:10.3390/jof7060480 · Cited by 19
Pfaller, M. A., Carvalhaes, C. G., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115473 · Cited by 18
Fungal Genomics in Respiratory Medicine: What, How and When?
Brackin, A. P., Hemmings, S., Fisher, M. C., & Rhodes, J. L. (2021) · Mycopathologia · doi:10.1007/s11046-021-00573-x · Cited by 16
Ceragenin-Coated Non-Spherical Gold Nanoparticles as Novel Candidacidal Agents
Skłodowski, K., Chmielewska, S. J., Depciuch, J., Deptuła, P., Piktel, E., Daniluk, T., Zakrzewska, M., Czarnowski, M., Cieśluk, M., Durnaś, B., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111940 · Cited by 16
“Most importantly, these species are more likely to be resistant to commonly used antifungal drugs and demonstrate the potential to lead to outbreaks [6].”
BackgroundInfluentialWater-Soluble Nystatin and Derivative
Amir, A., Levin-Khalifa, M., & Dvash, T. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00538 · Cited by 20
Marena, G. D., Ramos, M. A. D. S., Carvalho, G. C., Paris, J. A., Resende, F. A., Corrêa, I., Ono, G. Y. B., Araújo, V. H. S., de Camargo, B. A. F., Bauab, T. M., et al. (2022) · Phytotherapy Research · doi:10.1002/ptr.7460 · Cited by 20
Cai, L., Gao, P., Wang, Z., Dai, C., Ye, N., İlkit, M., Xue, X., Xiao, J., & Chen, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988708 · Cited by 18
“Recent global estimates revealed that 8,000,000 cases of PA occur annually (8).”
BackgroundA Simple Nematode Infection Model for Studying Candida albicans Pathogenesis
Kim, G. H., Rosiana, S., Kirienko, N. V., & Shapiro, R. S. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.114 · Cited by 18
Alligamycin A, an antifungal β-lactone spiroketal macrolide from Streptomyces iranensis
Yang, Z., Qiao, Y., Strøbech, E., Morth, J. P., Walther, G., Jørgensen, T. S., Lum, K. Y., Peschel, G., Rosenbaum, M. A., Previtali, V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53695-3 · Cited by 18
Brandt, P., Singha, R., & Ene, I. V. (2024) · mBio · doi:10.1128/mbio.03045-23 · Cited by 20
Garlic-Derived Quorum Sensing Inhibitors: A Novel Strategy Against Fungal Resistance
Li, N., Zhang, J., Yu, F., Ye, F., Tan, W., Hao, L., Li, S., Deng, J., & Hu, X. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s503302 · Cited by 19
Schmidt, T. E., Vieceli, T., Damasceno, L. S., Kimuda, S., Pasqualotto, A. C., & Bahr, N. C. (2025) · Journal of Fungi · doi:10.3390/jof11030196 · Cited by 23
“In 2017, the total estimated annual incidence of histoplasmosis was ~100,000 cases worldwide [15].”
Wychrij, D. A., Chapman, T. I., Rayens, E. A., Rabacal, W., Willems, H. M. E., Oworae, K. O., Peters, B. M., & Norris, K. A. (2025) · npj Vaccines · doi:10.1038/s41541-025-01171-4 · Cited by 16
“…fungal infections are associated with high mortality, with global estimates of over 6.5 million cases and 3.8 million deaths annually 1 , super fi cial and mucosal manifestations account for the highest morbidity, with over a billion individuals estimated to be affected by these infections 2 .”
InfluentialToyotome, T., Onishi, K., Sato, M., Kusuya, Y., Hagiwara, D., Watanabe, A., & Takahashi, H. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02657-20 · Cited by 17
Tharappel, A. M., Li, Z., Zhu, Y. C., Wu, X., Chaturvedi, S., Zhang, Q., & Li, H. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00137 · Cited by 15
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.